Thermo Fisher Scientific to Power All Current U.S. Sites With 100 Percent Renewable Electricity

 

  Thermo Fisher's latest net-zero milestone to be achieved through 200-megawatt solar project  

 

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it will power all of the company's current U.S. sites with 100 percent renewable electricity by 2026. The company's new 20-year virtual power purchasing agreement with EDF Renewables includes the full output of the 200-megawatt (MW) Millers Branch Solar project.

 

The agreement with EDF Renewables will deliver approximately 545,000 MWh of renewable electricity annually from the Millers Branch Solar project in Texas. This project complements Thermo Fisher's previously announced agreement with Enel North America for the Seven Cowboy wind project. Together, these projects will provide enough renewable power to match all of Thermo Fisher's current U.S. electricity needs.

 

"Transitioning away from fossil fuels and adopting renewable energy accelerates our progress toward net-zero carbon emissions by 2050," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Our agreement with EDF Renewables further demonstrates our commitment to addressing climate change and creating a more sustainable world for all—a goal that is deeply rooted in our Mission to enable our customers to make the world healthier, cleaner and safer."

 

The impact of the company's U.S. transition to renewable electricity contributes significantly to Thermo Fisher's recently announced commitment to raise its 2030 reduction target for Scope 1 and 2 greenhouse gas emissions—from 30% to 50%, based on a 2018 baseline. 1 The new 50% reduction target, announced in December 2022 , fulfills Thermo Fisher's commitment to the Business Ambition to 1.5˚C campaign and aligns its climate strategy with the Paris Agreement and its reduction targets with the 1.5˚C pathway.

 

Thermo Fisher has submitted its climate targets to the Science Based Targets initiative (SBTi) for validation. SBTi establishes standards, guidance, and tools to drive ambitious climate action in the private sector. Thermo Fisher is among the first companies in its sector to submit net-zero climate targets to SBTi.

 

The Millers Branch Solar project is expected to be operational by December 2025. Thermo Fisher was supported by Sustainability Roundtable Inc.'s Net Zero Consortium for Buyers, a platform committed to helping corporate buyers with global decarbonization strategies and favorable renewable energy transactions.

 

More information about Thermo Fisher's environmental, social, and governance progress can be found at www.thermofisher.com/csr .

 

  About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

 

  1 New target is 50.4%. Both targets from a 2018 baseline.

 

  

  

Media:
Sandy Pound
781-622-1223
sandy.pound@thermofisher.com  

 

Investors:
Rafael Tejada
781-622-1356
rafael.tejada@thermofisher.com  

 

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×